



**HAL**  
open science

## Association of chorioamnionitis with cerebral palsy at two years after spontaneous very preterm birth: the epipage-2 cohort study

Emeline Maisonneuve, Elsa Lorthe, Heloise Torchin, Pierre Delorme, Louise Devisme, Stephane Marret, Damien Subtil, Florence Bodeau-Livinec, Veronique Pierrat, Loic Sentilhes, et al.

### ► To cite this version:

Emeline Maisonneuve, Elsa Lorthe, Heloise Torchin, Pierre Delorme, Louise Devisme, et al.. Association of chorioamnionitis with cerebral palsy at two years after spontaneous very preterm birth: the epipage-2 cohort study. *The Journal of Pediatrics*, 2020, *The Journal of pediatrics*, 222, pp.71-78.e6. 10.1016/j.jpeds.2020.03.021 . hal-03405174

**HAL Id: hal-03405174**

**<https://hal.univ-lille.fr/hal-03405174v1>**

Submitted on 23 Jun 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## TITLE PAGE

### Manuscript title

Association of Chorioamnionitis with Cerebral Palsy at Two Years after Spontaneous Very Preterm Birth: The EPIPAGE-2 Cohort Study

### Author names

Emeline Maisonneuve, MD.<sup>1,2</sup>  
Elsa Lorthe, RM, PhD<sup>1,3</sup>  
Héloïse Torchin MD, PhD<sup>1,4,5</sup>  
Pierre Delorme, MD<sup>1,4,6</sup>  
Louise Devisme, MD<sup>7</sup>  
Laurence Foix L'Hélias, MD, PhD<sup>1,4,8</sup>  
Stéphane Marret, MD, PhD<sup>9,10</sup>  
Damien Subtil, MD, PhD<sup>11,12</sup>  
Florence Bodeau-Livinec, MD, PhD<sup>1,13</sup>  
Véronique Pierrat, MD, PhD<sup>1,14</sup>  
Loïc Sentilhes, MD, PhD<sup>15</sup>  
François Goffinet, MD, PhD<sup>1,4,6</sup>  
Pierre-Yves Ancel<sup>1,4,16</sup>, MD, PhD<sup>1</sup>  
Gilles Kayem, MD, PhD<sup>1,4,17</sup>  
For the EPIPAGE-2 Obstetric writing group

<sup>1</sup> Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité, INSERM U1153, Paris, France

<sup>2</sup> Department of Fetal Medicine, Hôpital Armand Trousseau, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France

<sup>3</sup> EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal

<sup>4</sup> Paris Descartes University, France

<sup>5</sup> Neonatal Intensive Care Unit, Hôpital Cochin, Paris, France

<sup>6</sup> Department of Obstetrics and Gynecology, Maternité Port-Royal, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, DHU Risques et Grossesse, Paris, France

<sup>7</sup> Department of Pathology, Lille University Hospital CHRU, Lille, France

<sup>8</sup> Neonatal care unit, Hôpital Armand Trousseau, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France

<sup>9</sup> Neonatal pediatrics and intensive care unit, Neuropediatrics Department, Centre de référence des troubles des apprentissages de l'enfant, CAMPS, Hôpital Charles Nicolle, Rouen

<sup>10</sup> INSERM U1245 – Neovasc team - Perinatal handicap, Institute of Biomedical Research and Innovation, Normandy University, Rouen, France

<sup>11</sup> CHU Lille, Department of Obstetrics and Gynaecology, Jeanne de Flandre Hospital, F-59000 Lille, France

<sup>12</sup> A 4489, Lille North of France University, Lille, France

<sup>13</sup> Ecole des Hautes Etudes en Santé Publique, Rennes, France

<sup>14</sup> CHU Lille, Department of Neonatal Medicine, Jeanne de Flandre Hospital, F-59000 Lille, France

<sup>15</sup> Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France

<sup>16</sup> Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris, France

<sup>17</sup> Department of Obstetrics and Gynecology, Hôpital Armand Trousseau, Sorbonne University, Assistance Publique-Hôpitaux de Paris, France

**Corresponding author:**

Emeline Maisonneuve, MD  
Obstetrical, Perinatal and Pediatric Epidemiology Research Team  
Center for Epidemiology and Statistics Sorbonne Paris Cité  
INSERM U1153,  
Cochin Hospital, Assistance Publique-Hôpitaux de Paris  
53, avenue de l'Observatoire  
75014 PARIS  
FRANCE  
+33 7 60 72 25 71, fax: +33 1 44 73 63 82  
emelinem@yahoo.com

**SHORT TITLE** (6 words/max 8 words)

Association of chorioamnionitis with cerebral palsy

**FUNDING**

The EPIPAGE-2 Study was supported by the French Institute of Public Health Research/Institute of Public Health and its partners the French Health Ministry, the National Institute of Health and Medical Research, the National Institute of Cancer, and the National Solidarity Fund for Autonomy; grant ANR-11-EQPX-0038 from the National Research Agency through the French Equipex Program of Investments in the Future; and the PremUp Foundation.

## **STRUCTURED ABSTRACT (248 words)**

**Objective:** To assess whether chorioamnionitis is associated with cerebral palsy (CP) or death at 2 years' corrected age in infants born before 32 weeks of gestation (WG) after spontaneous birth.

**Study design:** EPIPAGE-2 is a national, prospective, population-based cohort study of preterm children born in France in 2011; recruitment periods varied by gestational age. This analysis includes infants born alive after preterm labor or preterm premature rupture of membranes from 24<sup>+0</sup> to 31<sup>+6</sup>WG. We compared the outcomes of CP, death at 2 years' corrected age, and "CP or death at age 2" according to the presence of either clinical chorioamnionitis (CCA) or histological chorioamnionitis (HCA). All percentages were weighted by the duration of the recruitment period.

**Results:** Among 2,252 infants born alive spontaneously before 32 WG, 116 (5.2%) were exposed to CCA. Among 1,470 with placental examination data available, 639 (43.5%) had HCA. In total, 346 infants died before 2 years and 1,586 (83.2% of the survivors) were evaluated for CP at age 2. CP rates were 11.1% with and 5.0% without CCA ( $P=.03$ ) and 6.1% with and 5.3% without HCA ( $P=.49$ ). After adjustment for confounding factors, CP risk rose with CCA (adjusted OR [aOR] 2.13, 95% CI 1.12-4.05) but not HCA (aOR 1.21, 95% CI 0.75-1.93). Neither form was associated with the composite outcome "CP or death at age 2".

**Conclusions:** Among very preterm infants born spontaneously, the risk of CP at a corrected age of two years was associated with exposure to CCA but not HCA.

**Keywords:** cerebral palsy; chorioamnionitis; intrauterine infection; cohort study; preterm birth

## **Abbreviations:**

<b>aOR</b>	<b>adjusted odds ratio</b>
<b>CCA</b>	<b>clinical chorioamnionitis</b>
<b>CI</b>	<b>confidence interval</b>
<b>CP</b>	<b>cerebral palsy</b>
<b>GA</b>	<b>gestational age</b>
<b>HCA</b>	<b>histological chorioamnionitis</b>
<b>IVH</b>	<b>intraventricular hemorrhage</b>
<b>PPROM</b>	<b>preterm premature rupture of the membranes</b>
<b>PTL</b>	<b>preterm labor</b>
<b>WG</b>	<b>weeks of gestation</b>

## **MAIN TEXT**

### **Introduction**

Cerebral palsy (CP), the most common cause of motor deficiency in young children, occurs in about 5% of very premature births.<sup>(1-3)</sup> It has been suggested that chorioamnionitis, either clinical (CCA) or histological (HCA), is associated with CP.<sup>(4,5)</sup> Definitions of prenatal inflammation/infection vary widely, and its impact on the fetal brain remains controversial.<sup>(6)</sup> Three meta-analyses have shown conflicting results about an association between chorioamnionitis and CP in premature infants.<sup>(5, 7-9)</sup> Most previous studies have included children born prematurely without distinguishing the causes of these preterm deliveries, primarily, placental vascular disease, preterm premature rupture of membranes (PPROM), or preterm labor (PTL).<sup>(10, 11)</sup> However, the clinical path leading to preterm birth, including fetal and obstetric complications and mode of delivery, differs in women with vascular disorders and those with PTL and PPRM.<sup>(12)</sup> Inflammation may be involved in cases of PTL or PPRM and lead to spontaneous preterm birth, whereas vascular disease is associated with placental insufficiency,

medically induced prematurity, and higher in-hospital mortality.<sup>(12, 13)</sup> Including all subtypes of preterm births may thus be inappropriate, first, because chorioamnionitis is nearly absent in the subgroup of infants with vascular disease,<sup>(14)</sup> and second, because adverse outcomes are induced by different physiopathological pathways that depend on the preterm birth subtype.<sup>(12, 13, 15, 16)</sup> Intrauterine inflammation with elevated fetal cytokines may be independently harmful for the preterm infant's developing brain and provoke neonatal cerebral white matter damage that may subsequently be diagnosed as CP.

Thus, we studied the impact of chorioamnionitis on CP and/or death in a homogeneous population of infants born after PTL or PPRM in the EPIPAGE-2 cohort, a French prospective population-based study.<sup>(17)</sup> The main objective was to assess the association between CCA and/or HCA and CP at a corrected age of two years in children born before 32 WG.

## **Methods**

EPIPAGE-2 is a nationwide, prospective, population-based study scheduled to follow up preterm children to the age of 12 years.<sup>(18)</sup> Neonates born from 22 to 34 completed WG in France were eligible for inclusion. Recruitment took place in 2011 in all maternity units in 25 participating regions accounting for 98% of all births in France. Inclusions lasted 8 months for preterm births from 22<sup>+0</sup> to 26<sup>+6</sup>WG, 6 months for those from 27<sup>+0</sup> to 31<sup>+6</sup>WG, and 5 weeks for those from 32<sup>+0</sup> to 34<sup>+6</sup>WG.<sup>(17)</sup> Referring physicians assessed the presence of CP or other neurosensory deficiencies at two years' corrected age.

## ***Ethics***

The National Data Protection Authority (CNIL no.911009) and the appropriate ethics committees (Consultative Committee on the Treatment of Data on Personal Health for Research Purposes, no. 10.626; Committee for the Protection of People Participating in Biomedical Research, CPP SC-2873) approved the study. Recruitment occurred only after families had received information and data collection only after they consented to participate in the study.

## ***Participants***

Singletons and twins born alive from 24<sup>+0</sup> to 31<sup>+6</sup>WG after a spontaneous birth involving PPROM (rupture of the membranes more than 24 hours before delivery) or PTL (defined as regular contractions accompanied by cervical change, including intact membranes and membranes ruptured for less than 24 hours before delivery) were included in this study. The method of classifying the cause of preterm birth has previously been described.<sup>(13)</sup>

Exclusion criteria were: other causes of preterm birth; births before 24 WG because such infants did not routinely receive intensive care in France in 2011;<sup>(18)</sup> births after 32 weeks because CP occurs in 1% of infants born later;<sup>(2)</sup> and severe congenital malformations, prenatal cytomegalovirus and toxoplasmosis infections, fetal alcohol syndrome, and congenital hypothyroidism, all repeatedly associated with CP.<sup>(4)</sup> Four authors (EM, LFH, GK, and FG) independently reviewed cases of congenital anomalies. We also excluded all triplets and quadruplets, as well as twin pregnancies with complications, such as twin-twin transfusion syndrome or intrauterine fetal death of one co-twin, because of the intermediate factors of morbidity in multiple pregnancies.<sup>(4)</sup>

## ***Main outcomes and exposure measures***

### *CCA and HCA*

CCA was diagnosed by maternal temperature  $>37.8^{\circ}\text{C}$  ( $100^{\circ}\text{F}$ ) associated with at least two of the following five criteria: maternal tachycardia  $>100$  beats/min, fetal baseline tachycardia  $>160$  beats/min, uterine tenderness, maternal leukocytosis  $>15,000$  cells/ $\text{mm}^3$ , and foul-smelling vaginal discharge or amniotic fluid.<sup>(19)</sup>

Within the EPIPAGE-2 study, the CHORHIST project was specifically designed to study the impact of HCA on neurological outcomes, from data collected by pathologists with a standardized form to assess the extent of HCA and funisitis.<sup>(17)</sup> According to this standardized classification, histological placental findings were divided into three stages: no HCA; HCA defined by the presence of neutrophils in the membranous amniochorion and/or membranes; and HCA

with histological funisitis, defined by neutrophil infiltration into the fetal vessels in the chorionic plate and umbilical cord.<sup>(20)</sup>

#### *Outcomes: cerebral palsy and death*

The primary outcome was CP, a disease due to permanent movement and posture disturbances resulting from a nonprogressive lesion of the developing brain. It was defined according to the diagnostic criteria of the Surveillance of Cerebral Palsy in Europe network.<sup>(3)</sup> Data for children at 2 years of corrected age were collected with a standardized questionnaire completed by the referring physician.

The secondary outcome was a composite outcome, "CP or death", which included infants who died before the age of two years and those who presented CP at that age, to take the potential competitive risk between these outcomes into account.

#### *Other factors studied*

Maternal characteristics examined were age, region of birth, personal health insurance coverage, obesity (body mass index  $\geq 30$  kg/m<sup>2</sup>) and addictions (smoking, alcohol, or drugs). Obstetric characteristics were parity, number of fetuses, cervical cerclage, PPRM, antenatal corticosteroids, antenatal magnesium sulfate, "inborn" status, antenatal antibiotics, mode of delivery, and gestational age (GA). Antenatal steroid treatment was defined by administration to the mother of at least one betamethasone injection.

The neonatal variables examined were gender, birth weight, death in the delivery room or neonatal intensive care unit, early-onset sepsis, necrotizing enterocolitis (Bell's stage  $\geq 2$ ), severe bronchopulmonary dysplasia, severe intraventricular hemorrhage (IVH), and cystic periventricular leukomalacia. Early-onset sepsis was defined as proven neonatal bacterial infection with positive cultures of cerebrospinal fluid or blood before 72 hours of life. Severe bronchopulmonary dysplasia was defined as oxygen supplementation for at least 28 days and persistent need for oxygen ( $\text{FiO}_2 \geq 30\%$ ) and/or ventilatory support (mechanical ventilation or positive pressure) at 36 weeks' postmenstrual age.<sup>(21)</sup> The criteria for IVH required its association



with ventricular dilatation (grade III IVH) or intraparenchymal hemorrhage (grade IV IVH), based on the Papile grading system.<sup>(22)</sup> Cystic periventricular leukomalacia was defined by periventricular white-matter echolucencies associated with cavitation on ultrasonography.<sup>(23)</sup>

### ***Statistical analysis***

Categorical variables were compared by a Chi-square test or Fisher's exact test, as appropriate. Continuous variables were described by their medians and interquartile ranges (IQR) and were compared by rank-sum tests. All percentages, medians, and crude ORs were weighted to account for the different durations of recruitment for different gestational-age categories of preterm birth, based on their frequencies. Percentages are expressed as weighted percentages (wtd%).

Because the associations of HCA alone and HCA + funisitis with CP, death, and "CP or death" were similar, the following analyses treat HCA and HCA + funisitis as the same exposure variable. PTL and PPROM were considered together for the same reason (Table I; online only).

The associations between CCA and HCA with CP, death, and "CP or death" at age 2 were studied by bivariate analyses and multivariate logistic regression models that used generalized estimated equations to take the non-independence of observations for twins into account. These analyses were performed for cases with available data for either CCA or HCA and were adjusted for maternal age, obesity, number of fetuses, GA at birth, gender, and antenatal steroid use, because these potential confounding factors have previously been associated with CP in the literature.<sup>(1, 4,</sup>

<sup>24)</sup> Adjusting for GA is customary in observational studies comparing groups with different GA compositions, even if this factor is probably more an intermediate than a confounding variable.<sup>(25)</sup>

Missing data rates ranged from 0% to 1.7% for the covariates included in the multivariate analyses, 16.8% for the primary outcome (CP), and 0% for death. Missing data for the covariates were considered missing at random. We performed two analyses: 1) a complete-case analysis (logistic regression restricted to infants with complete data for the diagnosis of CCA or HCA, the outcome, and all covariates); 2) an analysis after multiple imputations for missing data for all covariates and the main outcome, with a logistic regression imputation model for binary

variables. The imputation model included variables predicting nonresponse and/or correlated with outcomes (maternal, obstetric, and neonatal characteristics, severe IVH, cystic periventricular leukomalacia, bronchopulmonary dysplasia, necrotizing enterocolitis, early- and late-onset sepsis, postnatal corticotherapy, physiotherapy, blindness, and deafness at two years); 3) an analysis after multiple imputations for missing data for all covariates but not for CP, with a logistic regression imputation model for binary variables. Missing data were imputed by chained equations with the R package “mice” v2.25. Conversely, placental examination was missing for 34.7% of cases. These data were not imputed because they were not missing at random (Table II; online only). *P*-values < .05 were considered statistically significant. Statistical analyses used R v3.5.1.

## Results

Among the 3,816 live births eligible from the EPIPAGE-2 study, 329 were excluded because of congenital malformations or diseases, or as triplets or quadruplets or as twins with twin-twin transfusion syndrome, and 85 more for missing CCA data. Then 1,150 cases were excluded because the cause of preterm birth was neither PTL nor PPROM. Table III (online only) describes the distribution of CCA and HCA by cause of preterm birth. Finally, the analysis of the association between CCA and outcomes at 2 years included 2,252 children, of whom 1,470 had a placental examination available to enable analysis of the association of HCA with outcomes at age 2 (Figure I). The remaining 782 (34.7%) women had no placental examination. Factors associated with this lack of examination were maternal birth in sub-Saharan Africa, GA > 28 weeks, absence of CCA, and vaginal delivery, but not CP. (Table II; online only).

Of these 2,252 infants, 116 (5.2%) were exposed to CCA and 639/1,470 (43.5%) to HCA (with all percentages weighted according to the length of the recruitment period). Among these 1,470 children, 82 (5.5%) were exposed to both CCA and HCA and 557 (39.1%) to HCA but not CCA.

On bivariate analysis, CCA was associated with maternal age >35, nulliparity, obesity, singleton pregnancy, PPRM, antenatal antibiotics, GA <28 weeks, cesarean delivery, early-onset sepsis, and CP. HCA was associated with maternal birth in sub-Saharan Africa, no medical insurance, obesity, singleton pregnancy, cervical cerclage, PPRM, antenatal antibiotics, GA <28 weeks, early-onset sepsis, neonatal death, and death at age 2 (Table IV).

In all, 346 infants (267 born at 24–26 WG and 79 at 27–31 WG) died before age 2. Among the 1,906 children alive at two years, 1,586 were evaluated for CP and 320 (16.8%) lost to follow up. Among the latter, 16 (5.0%) were exposed to CCA and 83 (40.5%) to HCA, that is, they did not differ for this exposure (Table IV).

Overall, 85 (5.3%) children were diagnosed with CP. More specifically, at two years' corrected age, the CP rate was 11.1% in chorioamnionitis-exposed and 5.0% in non-exposed children ( $P=.03$ ). Associations of maternal, obstetric and neonatal characteristics with CP are reported in table V (online only). After multivariate analysis and multiple imputation, CCA exposure was associated with CP (aOR 2.13, 95% CI 1.12–4.05] but not with death (aOR 1.10, 95% CI 0.60–1.92) or with the composite "CP or death" outcome (aOR 1.42, 95% CI 0.87–2.26) (Table VI). HCA was not associated with CP (6.1% versus 5.3% with and without HCA; aOR = 1.21, 95% CI 0.75–1.93), death (aOR 0.87, 95% CI 0.62–1.23), or "CP or death" (aOR 0.89, 95% CI 0.66–1.19). Results were similar for CCA + HCA and CCA alone. Likewise, associations with CP, death, or "CP or death" were similar with HCA without CCA and with HCA alone (Table VI). Similar associations were observed without imputation for CP (Table VII; online only).

## **Discussion**

The primary finding of this study is that among very preterm infants born after PTL or PPRM, those with CCA were at increased CP risk; those with HCA were not.

The main strength of the study is its large prospective population-based design, with detailed data for pregnancy and neonatal outcomes. The second strength is the analysis of the association

between chorioamnionitis and CP in a large homogeneous population of very preterm infants born after PTL or PPROM.<sup>(16, 17)</sup>To that end, we excluded preterm children born after pregnancies complicated by fetal growth restriction or placental dysfunction because of the different physiological mechanisms leading to preterm birth and their poor outcomes for neonatal mortality, CP at two years, and cognitive function at age 5.<sup>(1, 13, 26)</sup>Another strength is the homogeneous data collection for the placentas examined, based on a form designed for the EPIPAGE-2 study and used prospectively for the histological analyses.

The rate of missing data for histological examination, although a limitation of our study, does not bias our findings. It is normal to send placentas for this examination in the most severe cases, such as those with CCA or delivery at an early GA. This weakness may thus artificially increase the prevalence of HCA in our population but it does not modify the potential association between HCA and CP.

Another potential limitation of our study is the 16.8% rate of missing data about CP at two years. This rate is nonetheless similar to that in other large studies of infants' outcome at two years.<sup>(10, 11)</sup>To provide the best estimate of the association of CP with CCA and HCA and to address this limit on the primary outcome, we used a model with multiple imputations to deal with missing data and including neonatal neurological data strongly associated with CP.<sup>(27)</sup>

The lack of use of magnesium sulfate for neuroprotection in 2011 in France also raises concern about the study's external validity. Nonetheless, magnesium sulfate administration should not modify the association between chorioamnionitis and CP, and its rate of administration was similar among the groups.<sup>(28)</sup>

The association between CCA or HCA and CP is controversial. Among the three meta-analyses that have studied it,<sup>(5, 7, 9)</sup>two found an increased risk of CP in cases of CCA. Interestingly, the strength of this association increased with the accuracy of the clinical criteria used to define CCA.<sup>(5, 7)</sup>The association between HCA and CP is even more controversial, and the most recent meta-analysis yielded discordant results, with aORs ranging from 0.35 to 2.48.<sup>(9, 29, 30)</sup>

Our findings come from the largest nationwide population-based prospective study we are aware of; its data about CCA and HCA are accurate and its practices consistent with current worldwide recommendations (i.e., antenatal corticosteroids for PTL or PPROM and antibiotics for PPROM). Moreover, no other study with a similar design has limited inclusion to women with PPROM and PTL. Two recent multicenter studies with large sample sizes did not find any association between HCA and CP, but they also included children born after placental disease.<sup>(10)</sup><sup>(11)</sup>In one of these studies, Pappas et al.<sup>(1)</sup> studied 1,194 children born before 27 WG and found CP rates of 4.9% in the cases with and 4.5% in those without HCA ( $P=.50$ ).<sup>(10)</sup> In 2016, in a retrospective study in Japan, Miyazaki et al reported similar rates of CP among 2,201 infants evaluated at 3 years (9.7% with and 6.3% without HCA; aOR 0.91, 95% CI 0.67-1.59).<sup>(11)</sup> These two studies, however, were not population-based and also included preterm births from all causes. They were therefore subject to potential biases, e.g., overrepresentation of growth-restricted infants not exposed to inflammation.

CP occurrence is now considered to be a complex primary motor developmental disorder secondary to the additional effects of multiple ante-, intra- or post-partum risk factors.<sup>(31)</sup> Our results suggest that when preterm birth is due to PTL or PPROM, CCA — but not HCA — is a risk factor for CP. Two potential hypotheses may explain this result. First, local inflammation may be stronger in CCA and produce greater effects on the fetus. Another hypothesis, however, is that many cases of histological chorioamnionitis are not caused by infection. Although inflammation has generally been considered to result from microbial presence in amniotic fluid, a host inflammatory response may instead, by its effect on cervical dilation or rupture of the membranes, promote microbial colonization and invasion. Some recent data support this hypothesis: recent studies of amniotic fluid that used both cultures and broad-range polymerase chain reaction combined with mass spectrometry have found that sterile intra-amniotic inflammation is more common than low virulence (e.g., *Ureaplasma* or *Mycoplasma* spp) microbial-associated intra-amniotic inflammation in women with preterm labor and as common in women

with PPROM. These findings suggest that sterile inflammation is more common and more closely associated with spontaneous preterm birth than is low virulence microbial-associated inflammation.<sup>(32, 33)</sup> HCA may therefore be sterile or associated with organisms of low virulence that have a milder impact, if any, on the neonatal brain.<sup>(34)</sup> Conversely, CCA is caused by highly pathogenic bacteria that are mostly group B Streptococcus and *Escherichia coli*,<sup>(19, 35)</sup> which can cause neonatal sepsis with higher neonatal morbidity and mortality.<sup>(36)</sup> CCA certainly represents a more recent set of events leading to premature delivery, while HCA reflects a broader list of etiologies over a longer period of time during pregnancy.

Our findings support current obstetric practices, especially for the management of PPROM before 32WG, in the absence of obstetric complications. Expectant management benefits the fetus by increasing GA at birth.<sup>(37-39)</sup> In cases of CCA, however, immediate delivery must be discussed. The possible risks caused by CCA have to be weighted against, for example, the risks of extreme prematurity.<sup>(38, 40)</sup>

## **Conclusion**

In this large prospective national population-based cohort study, among very preterm infants born after PTL or PPROM, we found that clinical chorioamnionitis was associated with an increased risk of CP, whereas HCA was not. However, analyses of long-term development with detailed data on cognitive and behavioral functions to confirm these findings are warranted to study the neurological consequences of intrauterine exposure to subclinical inflammation.

## **ACKNOWLEDGMENTS:**

The EPIPAGE-2 obstetric writing group

## **DISCLOSURE OF INTEREST:**

The authors have no conflict of interest to disclose.

1. Tronnes H, Wilcox AJ, Lie RT, Markestad T, Moster D. Risk of cerebral palsy in relation to pregnancy disorders and preterm birth: a national cohort study. *Dev Med Child Neurol.* 2014;56:779-85.
2. Pierrat V, Marchand-Martin L, Arnaud C, Kaminski M, Resche-Rigon M, Lebeaux C, et al. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study. *BMJ.* 2017;358:j3448.
3. Surveillance of Cerebral Palsy in E. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. *Surveillance of Cerebral Palsy in Europe (SCPE).* *Dev Med Child Neurol.* 2000;42:816-24.
4. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. *Best Pract Res Clin Obstet Gynaecol.* 2004;18:425-36.
5. Shatrov JG, Birch SC, Lam LT, Quinlivan JA, McIntyre S, Mendz GL. Chorioamnionitis and cerebral palsy: a meta-analysis. *Obstet Gynecol.* 2010;116:387-92.
6. Higgins RD, Saade G, Polin RA, Grobman WA, Buhimschi IA, Watterberg K, et al. Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop. *Obstet Gynecol.* 2016;127:426-36.
7. Wu YW, Colford JM, Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. *JAMA.* 2000;284:1417-24.
8. Ylijoki M, Ekholm E, Haataja L, Lehtonen L, group Ps. Is chorioamnionitis harmful for the brain of preterm infants? A clinical overview. *Acta Obstet Gynecol Scand.* 2012;91:403-19.
9. Shi Z, Ma L, Luo K, Bajaj M, Chawla S, Natarajan G, et al. Chorioamnionitis in the Development of Cerebral Palsy: A Meta-analysis and Systematic Review. *Pediatrics.* 2017;139.
10. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. *JAMA Pediatr.* 2014;168:137-47.
11. Miyazaki K, Furuhashi M, Ishikawa K, Tamakoshi K, Hayashi K, Kai A, et al. Impact of chorioamnionitis on short- and long-term outcomes in very low birth weight preterm infants: the Neonatal Research Network Japan. *J Matern Fetal Neonatal Med.* 2016;29:331-7.
12. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet.* 2008;371:75-84.

- Preterm Birth as a Prognostic Factor for Mortality. *Obstet Gynecol.* 2016;127:40-8.
14. Torchin H, Lorthe E, Goffinet F, Kayem G, Subtil D, Truffert P, et al. Histologic Chorioamnionitis and Bronchopulmonary Dysplasia in Preterm Infants: The Epidemiologic Study on Low Gestational Ages 2 Cohort. *J Pediatr.* 2017;187:98-104 e3.
  15. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet.* 2010;376:631-44.
  16. Maisonneuve E, Ancel PY, Foix-L'Helias L, Marret S, Kayem G. Impact of clinical and/or histological chorioamnionitis on neurodevelopmental outcomes in preterm infants: A literature review. *J Gynecol Obstet Hum Reprod.* 2017;46:307-16.
  17. Ancel PY, Goffinet F, Group EW. EPIPAGE 2: a preterm birth cohort in France in 2011. *BMC Pediatr.* 2014;14:97.
  18. Perlberg J, Ancel PY, Khoshnood B, Durox M, Boileau P, Garel M, et al. Delivery room management of extremely preterm infants: the EPIPAGE-2 study. *Arch Dis Child Fetal Neonatal Ed.* 2016.
  19. Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. *J Infect Dis.* 1982;145:1-8.
  20. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation--a workshop report. *Placenta.* 2005;26 Suppl A:S114-7.
  21. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 2001;163:1723-9.
  22. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr.* 1978;92:529-34.
  23. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. *Behav Brain Res.* 1992;49:1-6.
  24. Zhang J, Peng L, Chang Q, Xu R, Zhong N, Huang Q, et al. Maternal obesity and risk of cerebral palsy in children: a systematic review and meta-analysis. *Dev Med Child Neurol.* 2019;61:31-8.



Epidemiol. 2011;174:1062-8.

26. Guellec I, Lapillonne A, Renolleau S, Charlaluk ML, Roze JC, Marret S, et al. Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction. *Pediatrics*. 2011;127:e883-91.
27. Marret S, Marchand-Martin L, Picaud JC, Hascoet JM, Arnaud C, Roze JC, et al. Brain injury in very preterm children and neurosensory and cognitive disabilities during childhood: the EPIPAGE cohort study. *PLoS One*. 2013;8:e62683.
28. Kamyar M, Manuck TA, Stoddard GJ, Varner MW, Clark E. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. *BJOG*. 2016;123:1161-6.
29. Nasef N, Shabaan AE, Schurr P, Iaboni D, Choudhury J, Church P, et al. Effect of clinical and histological chorioamnionitis on the outcome of preterm infants. *Am J Perinatol*. 2013;30:59-68.
30. Kent A, Lomas F, Hurrion E, Dahlstrom JE. Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. *J Paediatr Child Health*. 2005;41:186-90.
31. Mitha A, Foix-L'Helias L, Arnaud C, Marret S, Vieux R, Aujard Y, et al. Neonatal infection and 5-year neurodevelopmental outcome of very preterm infants. *Pediatrics*. 2013;132:e372-80.
32. Romero R, Miranda J, Chaemsathong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med*. 2015;28:1394-409.
33. Romero R, Miranda J, Chaiworapongsa T, Korzeniewski SJ, Chaemsathong P, Gotsch F, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Reprod Immunol*. 2014;72:458-74.
34. Galinsky R, Polglase GR, Hooper SB, Black MJ, Moss TJ. The consequences of chorioamnionitis: preterm birth and effects on development. *J Pregnancy*. 2013;2013:412831.
35. Johnson CT, Farzin A, Burd I. Current management and long-term outcomes following chorioamnionitis. *Obstet Gynecol Clin North Am*. 2014;41:649-69.

Microbiol Rev. 2014;27:21-47.

37. Lorthe E, Ancel PY, Torchin H, Kaminski M, Langer B, Subtil D, et al. Impact of Latency Duration on the Prognosis of Preterm Infants after Preterm Premature Rupture of Membranes at 24 to 32 Weeks' Gestation: A National Population-Based Cohort Study. *J Pediatr.* 2017;182:47-52 e2.
38. Schmitz T, Sentilhes L, Lorthe E, Gallot D, Madar H, Doret-Dion M, et al. Preterm premature rupture of the membranes: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). *Eur J Obstet Gynecol Reprod Biol.* 2019;236:1-6.
39. American College of O, Gynecologists' Committee on Practice B-O. Practice Bulletin No. 172: Premature Rupture of Membranes. *Obstet Gynecol.* 2016;128:e165-77.
40. Committee on Obstetric P. Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection. *Obstet Gynecol.* 2017;130:e95-e101.

## FIGURE LEGEND

**Figure I:** Study flow chart

Among 2,252 live births ( $N_2$ ), a placental examination was available for 1470 cases ( $N_5$ ).  
Among 1,586 infants evaluated for CP at 2 years ( $N_1$ ), a placental examination was available for 1018 cases ( $N_4$ ).

**Table IV:** Demographic and baseline characteristics and outcomes for infants born after preterm

		<b>No CCA</b>	<b>CCA</b>	<b>No HCA</b>	<b>HCA</b>
		(N=2136)	(N=116)	(N=831)	(N=639)
		n (wtd %)	n (wtd %)	n (wtd %)	n (wtd %)
<b>MATERNAL AND OBSTETRIC CHARACTERISTICS</b>					
Maternal age, years	<20	97 (4.6)	7 (5.6)	42 (5.0)	29 (4.7)
	20-35	1627 (76.2)	79 (68.4)	626 (75.2)	474 (74.3)
	>35	410 (19.2)	30 (25.9)*	163 (19.8)	134 (21.0)
Region of birth	Europe	1726 (80.8)	93 (80.2)	709 (85.3)	502 (78.6)
	North African	76 (3.6)	4 (3.4)	26 (3.1)	21 (3.3)
	Sub-Saharan African	90 (4.2)	3 (2.6)	17 (2.0)	38 (5.9)**
	Other	52 (2.4)	6 (5.2)	12 (1.4)	14 (2.2)
	<i>Missing data</i>	<i>192 (9.0)</i>	<i>10 (8.6)</i>	<i>67 (8.1)</i>	<i>64 (10.0)</i>
No medical insurance		224 (10.5)	11 (9.5)	72 (8.7)	77 (12.1)*
	<i>Missing data</i>	<i>216 (10.1)</i>	<i>17 (14.7)</i>	<i>64 (7.7)</i>	<i>81 (12.7)</i>
Smoker		474 (22.9)	28 (24.4)	178 (22.0)	157 (25.3)
Obesity		250 (12.9)	27 (26.5)**	92 (12.2)	104 (18.1)*
	<i>Missing data</i>	<i>201 (9.4)</i>	<i>11 (9.5)</i>	<i>70 (8.4)</i>	<i>49 (7.7)</i>
Nulliparity		1155 (54.2)	49 (43.5)*	465 (55.7)	334 (52.3)
Type of pregnancy	Singleton	1373 (64.0)	91 (78.3)*	485 (57.8)	462 (72.1)**
	Twin	763 (36.0)	25 (21.7)	346 (42.2)	177 (27.9)
Cerclage		158 (7.4)	11 (9.5)	40 (4.8)	65 (10.2)**
	<i>Missing data</i>	<i>143 (6.7)</i>	<i>7 (6.0)</i>	<i>57(6.9)</i>	<i>32 (5.0)</i>
PTL		1053 (49.4)	28 (23.6) **	469 (56.4)	230 (35.8) **
PPROM		1073 (50.6)	88 (76.4)**	355 (43.6)	409 (64.2)**
Antenatal corticosteroids		1713 (81.9)	91 (81.1)	667 (82.5)	534 (84.9)
Antenatal antibiotics		1374 (64.6)	102 (87.7)**	478 (57.9)	499 (78.2)**
Cesarean section		962 (46.5)	63 (56.7)*	414 (51.4)	286 (46.2)
CCA		-	-	13 (1.6)	82 (13.0)**
HCA (among available placentas)		557 (39.2)	82 (85.5)**	-	-
Gestational age	24 <sup>+0</sup> -27 <sup>+6</sup>	823 (33.5)	59 (46.1)*	262 (26.9)	367 (48.0)**
WG	28 <sup>+0</sup> -31 <sup>+6</sup>	1313 (66.5)	57 (53.9)	569 (73.1)	272 (52.0)
<b>NEONATAL CHARACTERISTICS AND OUTCOMES</b>					
Birth weight	Median (IQR)	1200 (590)	1065 (573)	1242 ± 361	1084 ± 347**
Male		1168 (54.6)	62 (53.5)	481 (57.6)	310 (48.3)**
Neonatal death		314 (12.7)	23 (18.1)	117 (12.0)	125 (17.5)*
Early-onset sepsis		53 (2.6)	8 (7.9)*	10 (1.3)	26 (4.6)**
IVH grade III or IV		180 (7.9)	10 (9.8)	63 (6.8)	59 (9.2)
Cystic periventricular leukomalacia		54 (2.6)	1 (0.8)	20 (2.5)	18 (2.8)
<b>INFANTS' OUTCOMES AT 2 YEARS</b>					
Death		323 (13.1)	23 (18.1)	119 (12.3)	128 (17.9)*
Cerebral palsy		76 (5.0)	9 (11.1)*	31 (5.3)	27 (6.1)
Lost to follow-up		304 (16.8)	16 (17.2)	122 (17.1)	83 (16.2)

wtd%: Percentages are weighted by recruitment period.

\*  $P < .05$ , \*\*  $P < .001$

Chi-2 and Fisher tests were performed with weighting by recruitment period.

For each variable in rows, if missing data > 5%, the numbers and percentages of missing data are added to a supplementary row.

**Table VI:** Association of chorioamnionitis with cerebral palsy and/or death at 2 years in very preterm births

	No chorioamnionitis n/N (wt'd %)	Chorioamnionitis n/N (wt'd %)	Crude OR (95% CI) <i>P</i> -value	aOR <sup>1</sup> (95% CI) <i>P</i> -value	aOR <sup>2</sup> (95%CI) <i>P</i> -value
<b>CCA (regardless of histological status)</b>					
CP N <sub>1</sub> =1586	76/1509 (5.0)	9/77 (11.1)	2.43 (1.11-5.33) <i>P</i> = .03	2.25 (0.99-4.61) <i>P</i> = .04	2.13 (1.12-4.05) <i>P</i> = .02
Death before age 2 N <sub>2</sub> =2252	323/2136 (13.1)	23/116 (18.1)	1.38 (0.86-2.22) <i>P</i> = .18	1.10 (0.57-2.01) <i>P</i> = .76	1.10 (0.60-1.92) <i>P</i> = .15
CP or death N <sub>3</sub> =1932	399/1832 (19.5)	32/100 (29.8)	1.64 (1.06-2.55) <i>P</i> = .03	1.53 (0.88-2.60) <i>P</i> = .12	1.42 (0.87-2.26) <i>P</i> = .15
<b>HCA (regardless of clinical status)</b>					
CP N <sub>4</sub> =1018	31/590 (5.3)	27/428 (6.1)	1.21 (0.70-2.07) <i>P</i> = .49	0.84 (0.46-1.53) <i>P</i> = .57	1.21 (0.75-1.93) <i>P</i> = .43
Death before 2 years N <sub>5</sub> =1470	119/831 (12.3)	128/639 (17.9)	1.47 (1.11-1.94) <i>P</i> = .008	0.88 (0.61-1.27) <i>P</i> = .51	0.87 (0.62-1.23) <i>P</i> = .43
CP or death N <sub>6</sub> =1265	150/709 (18.9)	155/556 (25.5)	1.42 (1.09-1.85) <i>P</i> = .03	0.90 (0.65-1.23) <i>P</i> = .49	0.89 (0.66-1.19) <i>P</i> = .45
<b>HCA and CCA</b>					
CP N <sub>4</sub> =1018	51/962 (5.1)	7/56 (11.5)	2.55 (1.01-5.59) <i>P</i> = .03	2.28 (0.90-5.08) <i>P</i> = .06	3.21 (1.73-5.94) <i>P</i> = .0002
Death before 2 years N <sub>5</sub> =1470	231/1388 (14.4)	16/82 (17.6)	1.21 (0.67-2.08) <i>P</i> = .54	0.88 (0.41-1.77) <i>P</i> = .73	0.87 (0.44-1.68) <i>P</i> = .69
CP or death N <sub>6</sub> =1265	282/1193 (21.3)	23/72 (29.1)	1.46 (0.87-2.45) <i>P</i> = .15	1.38 (0.72-2.54) <i>P</i> = .32	1.31 (0.74-2.28) <i>P</i> = .35
<b>HCA without CCA</b>					
CP N <sub>7</sub> =957	31/585 (5.3)	20/372 (5.3)	0.99 (0.56-1.74) <i>P</i> = .99	0.72 (0.36-1.38) <i>P</i> = .33	0.91 (0.58-1.43) <i>P</i> = .69
Death before 2 years N <sub>8</sub> =1375	116/818 (12.1)	112/557 (17.9)	1.49 (1.14-2.00) <i>P</i> = .007	0.92 (0.63-1.35) <i>P</i> = .68	0.89 (0.63-1.27) <i>P</i> = .53
CP or death N <sub>9</sub> =1185	147/701 (18.7)	132/484 (24.9)	1.40 (1.06-1.84) <i>P</i> = .02	0.82 (0.58-1.16) <i>P</i> = .27	0.85 (0.62-1.16) <i>P</i> = .30

Legend:

The study subpopulations are classified as:

N<sub>1</sub>: children evaluated for CP at 2 years of corrected age

N<sub>2</sub>: children with available outcome for survival at 2 years of corrected age

N<sub>3</sub>: children with available outcomes for CP or death at 2 years of corrected age

N<sub>4</sub>, N<sub>5</sub> and N<sub>6</sub> correspond to the same populations as N<sub>1</sub>, N<sub>2</sub> and N<sub>3</sub> respectively, restricted to the cases with available placental examinations.

N<sub>7</sub>, N<sub>8</sub> and N<sub>9</sub> correspond to the same populations as N<sub>4</sub>, N<sub>5</sub> and N<sub>6</sub> respectively, restricted to the cases without CCA, to study the impact of HCA only.


See the flow chart of the study (Figure 1) for the different subpopulations.

**aOR<sup>1</sup>**: Complete-case analysis, adjusted for GA, maternal age, obesity, antenatal corticosteroids, twinning and infant gender.

**aOR<sup>2</sup>**: Multiple imputations for covariates and outcome, restricted to cases with available diagnosis of CCA or placental histology, adjusted for GA, maternal age, obesity, antenatal corticosteroids, twinning, and infant gender.

Crude and adjusted ORs were calculated with generalized estimated equation models.

**Figure I:** Study flow chart



### **Additional members of the EPIPAGE-2 Obstetric Writing Group:**

**Catherine Arnaud**, MD, PhD (Research Unit on Perinatal Epidemiology, Childhood Disabilities and Adolescent Health, INSERM UMR 1027, Paul Sabatier University, Toulouse, France), **Chloé Arthuis** (Department of Gynecology and Obstetrics, CIC, University hospital of Nantes, Nantes, France), **Julie Blanc**, MD (Department of Obstetrics and Gynecology, Aix Marseille University, Marseille, France), **Pascal Boileau**, MD, PhD (Department of Neonatal Pediatrics, Poissy Saint Germain Hospital, France, EA7285 Versailles Saint Quentin en Yvelines University, France), **Thierry Debillon**, MD, PhD (Department of Neonatal Pediatrics, University Hospital, Grenoble, France), **Claude D'Ercole**, MD (Department of Obstetrics and Gynecology, Nord Hospital, Assistance Publique des Hôpitaux de Marseille (AP-HM), Aix Marseille Université, AMU, Marseille, France), **Thomas Desplanches**, RM, MSc (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France), **Caroline Diguisto**, MD, PhD (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France, Maternité Olympe de Gougues, University Francois Rabelais, Tours, France), **Aurélie Garbi**, MD (Department of Neonatology, Assistance Publique Hopitaux de Marseille, Marseille, France), **Géraldine Gascoin**, MD, PhD (Department of Neonatal Medicine, Angers University Hospital, Angers, France), **Catherine Gire**, MD (Department of Neonatology, North Hospital, Marseille, France), **Bruno Langer**, MD (Department of Obstetrics and Gynecology, Hautepierre Hospital, Strasbourg, France), **Mathilde Letouzey**, MD, MSc (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France, Department of Neonatal Pediatrics, Poissy Saint Germain Hospital, France), **Isabelle Monier**, RM, PhD (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France), **Andrei Morgan**, MD, PhD (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France), **Jean-Christophe Rozé**, MD, PhD (Department of Neonatal Medicine, Nantes University Hospital, Nantes, France, Epidémiologie Clinique, Centre d'Investigation Clinique (CIC004), Nantes University Hospital, Nantes, France), **Thomas Schmitz**, MD, PhD (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France, Department of Obstetrics and Gynecology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France), **Barthélémy Tosello**, MD, PhD (Department of Neonatology, Assistance Publique Hopitaux de Marseille, Marseille, France), **Christophe Vayssière**, MD, PhD (Department of Obstetrics and Gynecology, University Hospital, Toulouse, France, Research Unit on Perinatal Epidemiology, Childhood Disabilities and Adolescent Health, INSERM UMR 1027, Paul Sabatier University, Toulouse, France), **Norbert Winer**, MD, PhD (Department of Obstetrics and Gynecology, University Hospital, INRA, UMR 1280 Physiologie des adaptations nutritionnelles, Nantes, France), **Jennifer Zeitlin**, PhD (Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, F-75004 Paris, France).

All the collaborators of the EPIPAGE2 Obstetric writing group have no conflict of interest or compensation in relation with this article to disclose. All of them consented to such acknowledgment.

**Table III; online:** Distribution of clinical and histological chorioamnionitis/funisitis by cause of preterm birth in live births occurring between 24<sup>+0</sup> and 31<sup>+6</sup> weeks of gestation

Type of chorioamnionitis	Cause of preterm birth (N=3,402)				
	Spontaneous preterm birth (N=2,252)		Vascular disease (N=982)		Unknown or rare causes (N=168)
	PTL (N=1,400)	PPROM (N=852)	Hypertensive disorders and abruptio placenta (N=457)	Suspected FGR (N=525)	
n (%)	n (%)	n (%)	n (%)	n (%)	
<b>CCA</b>	41/1,400 (2.9)	75/852 (8.8)	1/457 (0.2) *	2/525 (0.4) *	3/168 (1.8)
<b>HCA alone</b>	306/896 (34.2)	333/574 (58.0)	7/336 (1.5) **	9/418 (1.7) **	19/124 (15.3)
<b>HCA + funisitis</b>	121/896 (13.5)	130/574 (22.6)	3/336 (0.7)	3/418 (0.6)	8/124 (6.4)
<b>No placental examination</b>	504/1,400 (36.0)	278/852 (32.6)	121/457 (26.5)	107/525 (20.4)	44/168 (26.2)

PTL: preterm labor, PPROM: preterm premature rupture of membranes, suspected FGR: fetal growth restriction < 10th percentile suspected prenatally based on estimated fetal weight, CCA: clinical chorioamnionitis, HCA: histological chorioamnionitis

Hypertensive disorder and abruptio placentae are cases not accompanied by suspected FGR.

Data on CCA were available for all cases. Data for HCA were available for 2,348/3,402 cases.

\* Three patients had mixed causes of prematurity: they presented criteria for CCA, but the main conditions leading to preterm birth were severe preeclampsia and HELLP syndrome, both with suspected FGR, and one case of abruptio placenta without suspected FGR.

\*\* Among the 16 cases of HCA associated with placental vascular disease, medical records revealed 8 had mixed causes of prematurity. The main cause of preterm birth was a history of placental dysfunction and the associated causes were CCA for 1, PPROM for 3 and PTL for 4.



**Table II; online:** Demographic and baseline characteristics and outcomes of cases with missing and available placental examination for determination of histological chorioamnionitis among infants born after preterm labor (PTL) or preterm premature rupture of membranes (PPROM)

		<b>Missing placentas N=782 n (%)</b>	<b>Available placentas N=1470 N (%)</b>	<b>Pvalue</b>
<b>MATERNAL AND OBSTETRIC CHARACTERISTICS</b>				
Maternal age, years	<20 20-35 >35	33 (4.2) 606 (77.5) 143 (18.3)	71 (4.8) 1100 (74.9) 297 (20.2)	.40
Region of birth	European North African Sub-Saharan African Others <i>Missing data</i>	608 (85.3) 33 (4.9) 38 (5.5) 32 (4.3) 71 (9.1)	1211 (90.4) 47 (3.5) 55 (4.1) 26 (1.9) 131 (8.9)	.002
No medical insurance	<i>Missing data</i>	86 (12.4) 88 (11.2)	149 (11.2) 145 (9.9)	.49
Smoking		167 (22.0)	335 (23.5)	.45
Nulliparity		405 (52.6)	799 (54.7)	.36
Number of fetuses	Singletons Twins	517 (66.1) 265 (33.9)	947 (64.4) 523 (35.6)	.45
PPROM		397 (51.1)	764 (52.2)	.60
Antenatal corticosteroids		603 (78.7)	1201 (82.9)	.02
Cesarean section		325 (41.6)	700 (47.9)	.01
Clinical chorioamnionitis		21 (2.7)	95 (6.5)	.0002
Gestational age, WG	24 <sup>+0</sup> -27 <sup>+6</sup> 28 <sup>+0</sup> -31 <sup>+6</sup>	253 (32.4) 529 (67.6)	629 (42.8) 841 (57.2)	<.0001
<b>NEONATAL CHARACTERISTICS</b>				
Birth weight	Mean ± SD	1273 ± 374	1173 ± 363	<.0001
Male gender		439 (56.1)	791 (53.8)	.31
<b>NEONATAL OUTCOMES</b>				
Neonatal death		95 (12.1)	242 (16.5)	.008
EOS		25 (3.5)	36 (2.7)	.40
<b>OUTCOMES AT 2 YEARS</b>				
Cerebral palsy		27 (4.8)	58 (5.7)	.49

WG: weeks' gestation, EOS: early-onset sepsis

For each variable in rows, in case of missing data over 5%, the numbers and percentages of missing data were added on a supplementary row.

**Table I; online:** Association between preterm premature rupture of membranes (PPROM), histological chorioamnionitis (HCA), alone or associated with funisitis, and cerebral palsy, death, and the composite outcome cerebral palsy or death among infants born after preterm labor (PTL) or PPROM

	Cerebral palsy at 2 years			Death at 2 years			Cerebral palsy or death		
	n/N (wtd%)	OR (95% CI)*	aOR (95% CI)**	n/N (wtd%)	OR (95% CI)*	aOR (95% CI)**	n/N (wtd%)	OR (95% CI)*	aOR (95% CI)**
PTL	55/992 (5.5)	ref	ref	216/1400 (13.3)	ref	ref	271/1208 (20.1)	ref	ref
PPROM	30/594 (5.0)	0.92 (0.58-1.45)	0.89 (0.56-1.40)	130/852 (13.3)	1.00 (0.78-1.29)	0.99 (0.76-1.31)	160/724 (20.0)	0.99 (0.79-1.25)	0.98 (0.76-1.25)
No HCA	31/590 (5.3)	ref	ref	119/831 (12.3)	ref	ref	150/709 (18.9)	ref	ref
HCA alone	12/211 (5.3)	1.05 (0.62-1.76)	0.87 (0.50-1.48)	61/315 (17.4)	1.43 (1.02-2.02)	0.80 (0.54-1.19)	73/272 (24.5)	1.37 (0.99-1.89)	0.81 (0.56-1.17)
HCA + funisitis	15/217 (6.9)	1.17 (0.70-1.97)	0.95 (0.55-1.60)	67/324 (18.4)	1.56 (1.12-2.17)	0.81 (0.55-1.19)	82/284 (26.5)	1.51 (1.11-2.07)	0.85 (0.59-1.22)

\* Percentages and unadjusted ORs are weighted (wtd%) by length of recruitment period

\*\* Adjusted for gestational age

**Table VII; online:** Association of chorioamnionitis and cerebral palsy (CP) and/or death at 2 years in very preterm births with no imputation for outcome

	No chorioamnionitis n/N (wtd %)	Chorioamnionitis n/N (wtd %)	Crude OR (95%CI) <i>P</i> value	aOR <sup>1</sup> (95%CI) <i>P</i> value	aOR <sup>2</sup> (95%CI) <i>P</i> -value
<b>CCA (regardless of histological status)</b>					
CP	76/1509 (5.0)	9/77 (11.1)	2.43 (1.11-5.33) <i>P</i> = .03	2.25 (0.99-4.61) <i>P</i> = .04	2.21 (1.00-4.87) <i>P</i> = .05
Death before 2 years	323/2136 (13.1)	23/116 (18.1)	1.38 (0.86-2.22) <i>P</i> = .18	1.10 (0.57-2.01) <i>P</i> = .76	1.10 (0.61-1.92) <i>P</i> = .74
CP or death	399/1832 (19.5)	32/100 (29.8)	1.64 (1.06-2.55) <i>P</i> = .03	1.53 (0.88-2.60) <i>P</i> = .12	1.48 (0.88-2.43) <i>P</i> = .13
<b>HCA (regardless of clinical status)</b>					
CP	31/590 (5.3)	27/428 (6.1)	1.21 (0.70-2.07) <i>P</i> = .49	0.84 (0.46-1.53) <i>P</i> = .57	1.03 (0.56-1.89) <i>P</i> = .92
Death before 2 years	119/831 (12.3)	128/639 (17.9)	1.47 (1.11-1.94) <i>P</i> = .008	0.88 (0.61-1.27) <i>P</i> = .51	0.84 (0.60-1.19) <i>P</i> = .33
CP or death	150/709 (18.9)	155/556 (25.5)	1.42 (1.09-1.85) <i>P</i> = .03	0.90 (0.65-1.23) <i>P</i> = .49	0.84 (0.62-1.16) <i>P</i> = .31

CCA: clinical chorioamnionitis, HCA: histological chorioamnionitis

wtd%, percentages are weighted by recruitment period

aOR<sup>1</sup>: Complete-case analysis, adjusted for gestational age, maternal age, obesity, antenatal corticosteroids, twinning, and infant gender.

aOR<sup>2</sup>: Multiple imputations for covariates, restricted to cases with available diagnosis of CCA or placental histology, adjusted for gestational age, maternal age, obesity, antenatal corticosteroids, twinning, and infant gender.

Crude and adjusted ORs were calculated with generalized estimated equation models.

**Table V; online:** Maternal, obstetric, and neonatal characteristics associated with cerebral palsy and/or death at 2 years: bivariate analysis

		No CP or death n=1501	CP n=85	CP or death n=431	CP Crude OR* [95%CI]	CP or death Crude OR* [95%CI]
<b>MATERNAL AND OBSTETRIC CHARACTERISTICS</b>						
Maternal age	<20	42 (2.8)	6 (7.1)	29 (6.8)	2.64 [0.98-5.95]	2.51 [1.54-4.08]
	20-35	1145 (76.3)	63 (74.1)	321 (74.8)	ref	ref
	>35	314 (20.9)	16 (18.8)	79 (18.4)	0.88 [0.45-1.58]	0.90 [0.66-1.21]
Ethnicity	White	1229 (89.4)	72 (93.5)	336 (87.5)	ref	ref
	North African	52 (3.8)	1 (1.3)	12 (3.1)	0.33 [0.18-1.53]	0.84 [0.42-1.55]
	Sub-Saharan African	59 (4.3)	4 (5.2)	25 (6.5)	1.16 [0.34-2.91]	1.55 [0.94-2.48]
	Other	34 (2.5)	0 (0)	11 (2.9)	-	1.18 [0.57-2.29]
	<i>Missing data</i>	127	8	47		
No medical insurance		116 (8.4)	11 (11.9)	56 (15.1)	1.93 [0.99-3.76]	1.97 [1.38-2.80]
	<i>Missing data</i>	122	10	60		
Nulliparity		834 (56.0)	45 (52.3)	233 (54.4)	0.87 [0.56-1.36]	0.93 [0.74-1.16]
Obesity		181 (13.0)	17 (22.1)	59 (16.0)	1.97 [1.13-3.43]	1.27 [0.91-1.77]
	<i>Missing data</i>	112	8	60		
History of psychiatric disease		34 (2.4)	3 (3.8)	14 (3.5)	1.63 [0.50-5.24]	1.49 [0.78-2.82]
History of addiction to alcohol		3 (0.2)	0 (0)	2 (0.005)	-	2.58 [0.42-15.99]
Drug use		26 (1.8)	1 (1.3)	4 (0.01)	0.72 [0.10-5.12]	0.56 [0.19-1.67]
Medically assisted reproduction		293 (19.7)	16 (19.9)	70 (16.8)	1.01 [0.58-1.77]	0.82 [0.61-1.11]
Medication in the first trimester		240 (16.7)	11 (13.9)	63 (15.3)	0.81 [0.42-1.56]	0.90 [0.66-1.24]
Gestational age	24 <sup>0</sup> -27 <sup>6</sup>	454 (30.2)	37 (43.5)	331 (76.8)	1.78 [1.14-2.76]	7.63 [5.97-9.83]
	28 <sup>0</sup> -31 <sup>6</sup>	1047 (69.8)	48 (56.5)	100 (23.2)	ref	ref
Number of fetuses	Singletons	917 (61.1)	63 (72.9)	310 (71.9)	ref	ref
	Twins	584 (38.9)	22 (27.1)	121 (28.1)	0.58 [0.35-0.95]	0.61 [0.48-0.77]
Antenatal corticosteroids		980 (67.1)	47 (56.0)	134 (45.4)	0.64 [0.41-1.01]	0.42 [0.34-0.53]
PPROM		768 (51.4)	44 (52.4)	220 (51.4)	1.02 [0.66-1.59]	1.00 [0.80-1.25]
CCA		68 (4.5)	9 (10.6)	32 (7.4)	2.43 [1.11-5.34]	1.75 [1.12-2.73]
HCA		401 (41.8)	27 (46.6)	155 (50.8)	1.21 [0.70-2.07]	1.42 [1.09-1.85]
HCA without CCA		352 (38.9)	20 (39.2)	132 (47.3)	1.21 [0.71-2.08]	1.44 [1.09-1.91]
	<i>Missing data</i>	541	27	126		
Cesarean section		751 (50.4)	33 (39.3)	133 (31.3)	0.65 [0.56-1.80]	0.47 [0.37-0.60]
<b>NEONATAL CHARACTERISTICS</b>						
Birth weight (g)	<1500	1061 (70.7)	67 (78.8)	404 (94.4)	1.54 [0.93-2.70]	6.98 [4.65-10.97]
	1500-2500	439 (29.2)	18 (21.2)	24 (5.6)	ref	ref
	>2500	1 (0.01)	0 (0)	0 (0)	-	-
Male gender		813 (54.2)	47 (55.3)	249 (57.8)	1.02 [0.66-1.59]	1.15 [0.92-1.44]
Severe IVH		53 (3.6)	10 (11.8)	126 (41.1)	3.90 [1.89-8.06]	19.4 [13.4-28.1]
cPVL		17 (1.1)	11 (12.9)	28 (9.6)	12.97 [5.78-29.1]	9.30 [5.0-17.4]
BPD		89 (6.1)	6 (13.9)	18 (9.0)	2.53 [1.24-5.14]	1.64 [0.93-2.89]
NEC		47 (3.2)	2 (2.4)	19 (6.1)	0.71 [0.16-3.16]	2.07 [1.18-3.65]
EOS		32 (2.2)	1 (1.2)	20 (6.5)	0.57 [0.08-4.01]	2.89 [1.59-5.24]

CP: cerebral palsy, CCA: clinical chorioamnionitis, HCA: histological chorioamnionitis, PPROM: preterm premature rupture of membranes, severe IVH: grade III or IV intraventricular hemorrhage, cPVL: cystic periventricular leukomalacia, BPD: bronchopulmonary dysplasia, NEC: necrotizing enterocolitis,

EOS: early-onset sepsis defined as proven neonatal bacterial infection with positive cultures of the cerebrospinal fluid or blood before 72 hours.

\* Unadjusted ORs are weighted by recruitment period

For each variable in rows, if missing data > 5%, the numbers and percentages of missing data are added to a supplementary row. There are no missing data for the following variables: maternal age, gestational age, number of fetuses, clinical chorioamnionitis, birth weight and male gender